Support HB2144: Biomarker Testing Coverage

**What does HB 2144 do?**

HB 2144 requires health insurers to cover comprehensive biomarker testing when supported by medical and scientific evidence. Biomarker testing helps connect patients with the most effective treatments for their disease.

Progress in improving cancer and other disease outcomes increasingly involves the use of precision medicine, which uses information about a person’s own genes or proteins to prevent, diagnose or treat diseases.

Biomarker testing is an important step to accessing precision medicine which includes targeted therapies that can lead to improved survivorship and better quality of life for cancer patients.

Biomarker testing can help providers determine which drugs or treatments are most likely to be effective for an individual patient. In other words, biomarker testing can help “match” patients to the right medicine.

Not all communities are benefitting from the latest advancements in biomarker testing and precision medicine, in part because insurance coverage for biomarker testing is failing to keep pace with innovations and advancements in treatment.

We must work to dismantle barriers that prevent patients from benefiting from biomarker testing and precision medicine, and work to ensure all patients benefit, regardless of race, ethnicity, gender, age, sexual orientation, socioeconomic status or zip code. Join ACS CAN in calling on the Arizona Legislature to require appropriate coverage of biomarker testing for public and private insurance plans.

*To learn more contact Brian Hummell, American Cancer Society Cancer Action Network (ACS CAN)
602.586.7414 | m: 602.319.8589 | brian.hummell@cancer.org*